| Date | Name | Symbol | Type | Security | Shares | Price | Value | Ownership | Reported |
| 08/17/2022 | Turning Point Therapeutics, Inc. | TPTX | Disposition | Common Stock | 41.3k | $76.00 | $3.1M | | 08/17/2022 |
| 08/17/2022 | Turning Point Therapeutics, Inc. | TPTX | Disposition | Stock Option (right to buy) | 169.2k | $54.73 | $9.3M | | 08/17/2022 |
| 08/17/2022 | Turning Point Therapeutics, Inc. | TPTX | Disposition | Stock Option (right to buy) | 29.2k | $140.01 | $4.1M | | 08/17/2022 |
| 08/17/2022 | Turning Point Therapeutics, Inc. | TPTX | Disposition | Stock Option (right to buy) | 68.4k | $37.68 | $2.6M | | 08/17/2022 |
| 02/09/2022 | Turning Point Therapeutics, Inc. | TPTX | Sale | Common Stock | 669 | $36.30 | $24.3k | | 02/09/2022 |
| 02/09/2022 | Turning Point Therapeutics, Inc. | TPTX | Grant | Common Stock | 19k | $0.00 | $0 | | 02/09/2022 |
| 02/09/2022 | Turning Point Therapeutics, Inc. | TPTX | Grant | Common Stock | 15k | $0.00 | $0 | | 02/09/2022 |
| 02/09/2022 | Turning Point Therapeutics, Inc. | TPTX | Grant | Stock Option (right to buy) | 68.4k | $37.68 | $2.6M | | 02/09/2022 |
| 02/08/2021 | Turning Point Therapeutics, Inc. | TPTX | Grant | Common Stock | 6.5k | $0.00 | $0 | | 02/08/2021 |
| 02/08/2021 | Turning Point Therapeutics, Inc. | TPTX | Grant | Stock Option (right to buy) | 29.2k | $140.01 | $4.1M | | 02/08/2021 |
| 01/05/2021 | Turning Point Therapeutics, Inc. | TPTX | Sale | Common Stock | 1.3k | $120.00 | $150.4k | | 01/04/2021 |
| 01/05/2021 | Turning Point Therapeutics, Inc. | TPTX | Exercise | Stock Option (right to buy) | 1.3k | $54.73 | $68.6k | | 01/04/2021 |
| 01/04/2021 | Turning Point Therapeutics, Inc. | TPTX | Sale | Common Stock | 8.7k | $120.42 | $1.1M | | 01/04/2021 |
| 01/04/2021 | Turning Point Therapeutics, Inc. | TPTX | Sale | Common Stock | 300 | $122.44 | $36.7k | | 01/04/2021 |
| 01/04/2021 | Turning Point Therapeutics, Inc. | TPTX | Exercise | Stock Option (right to buy) | 8.7k | $54.73 | $478.7k | | 01/04/2021 |
| 12/02/2019 | Turning Point Therapeutics, Inc. | TPTX | Grant | Stock Option (right to buy) | 179.2k | $54.73 | $9.8M | | 12/02/2019 |
| 09/28/2016 | MEDIVATION, INC. | MDVN | Other | Common Stock | 39.1k | $0.00 | $0 | | 09/28/2016 |
| 09/28/2016 | MEDIVATION, INC. | MDVN | Disposition | Common Stock | 18.7k | $0.00 | $0 | | 09/28/2016 |
| 09/28/2016 | MEDIVATION, INC. | MDVN | Disposition | Non-Qualified Stock Option (right to buy) | 24k | $8.64 | $207.4k | | 09/28/2016 |
| 09/28/2016 | MEDIVATION, INC. | MDVN | Disposition | Non-Qualified Stock Option (right to buy) | 60k | $3.79 | $227.6k | | 09/28/2016 |
| 09/28/2016 | MEDIVATION, INC. | MDVN | Disposition | Non-Qualified Stock Option (right to buy) | 16.9k | $27.43 | $463k | | 09/28/2016 |
| 09/28/2016 | MEDIVATION, INC. | MDVN | Disposition | Non-Qualified Stock Option (right to buy) | 11.7k | $35.96 | $422.1k | | 09/28/2016 |
| 09/28/2016 | MEDIVATION, INC. | MDVN | Disposition | Non-Qualified Stock Option (right to buy) | 3.5k | $52.85 | $182.9k | | 09/28/2016 |
| 09/28/2016 | MEDIVATION, INC. | MDVN | Disposition | Non-Qualified Stock Option (right to buy) | 13.6k | $60.53 | $820.7k | | 09/28/2016 |
| 09/28/2016 | MEDIVATION, INC. | MDVN | Disposition | Non-Qualified Stock Option (right to buy) | 2.4k | $42.50 | $101.2k | | 09/28/2016 |
| 09/28/2016 | MEDIVATION, INC. | MDVN | Disposition | Non-Qualified Stock Option (right to buy) | 38.5k | $35.77 | $1.4M | | 09/28/2016 |
| 09/28/2016 | MEDIVATION, INC. | MDVN | Disposition | Non-Qualified Stock Option (right to buy) | 1.1k | $46.45 | $52k | | 09/28/2016 |
| 09/28/2016 | MEDIVATION, INC. | MDVN | Disposition | Performance-Based Restricted Stock Units | 14.5k | $0.00 | $0 | | 09/28/2016 |
| 09/28/2016 | MEDIVATION, INC. | MDVN | Disposition | Stock Appreciation Rights | 58.8k | $11.60 | $681.9k | | 09/28/2016 |
| 09/15/2016 | MEDIVATION, INC. | MDVN | Exercise | Stock Option (Right to Buy) | 11.9k | $4.69 | $56k | | 09/15/2016 |
| 09/15/2016 | MEDIVATION, INC. | MDVN | Exercise | Stock Option (Right to Buy) | 5.6k | $4.00 | $22.5k | | 09/15/2016 |